Oncology Drug Shortages Persist
Inadequate vincristine supply highlights the need for strategies to avoid or mitigate a dearth of lifesaving therapies.
Prime Editing Promises Greater Precision, Safety
Newest CRISPR gene-editing tool fixes genetic glitches with fewer off-target alterations.
Cancer Collaboration Aims to Boost Detection
Consortium will develop and validate new methods for early diagnosis.
Tipifarnib Targets HRAS-Mutant Cancers
The farnesyltransferase inhibitor elicits responses, stable disease in head and neck squamous cell carcinoma.
NSCLC Evolution Linked to Biomarkers, Immune Dynamics
Latest insights from TRACERx could lead to new prognostic tests and cellular immunotherapies.
Case Made for MCLA-128 against NRG1 Fusion–Positive Cancers
Bispecific HER2/HER3 antibody yields radiologic and clinical responses in PDAC and NSCLC in proof-of-concept study.
Durvalumab Lengthens Survival in Extensive-Stage SCLC
Phase III CASPIAN trial shows that standard-of-care chemotherapy plus the PD-L1 inhibitor yields benefit for newly diagnosed patients.
Olaparib to Change Practice in mCRPC
The PARP inhibitor extended rPFS, improved ORR in patients with BRCA1/2 and ATM mutations.
Mammography Beneficial for Breast Cancer in Men
Research supports screening men at high risk of the disease.
Nobel Recognizes Discovery of Hypoxia Response Mechanism
Trio shares prize for establishing how cells sense and adapt to changing oxygen levels.
Immune System Research Underlies Lasker Awards
Scientists who identified B and T cells, as well as those who developed trastuzumab, capture coveted prizes.
Triplet Succeeds in Colorectal Cancer
Encorafenib, binimetinib, and cetuximab combo extends survival, improves responses in BRAF-mutant disease.
Osimertinib Holds Its Own in NSCLC
In final FLAURA analysis, osimertinib improves overall survival compared with older EGFR TKIs.
Success for First-Line PARP Inhibition in Ovarian Cancer
Data from three trials show that using the drugs as maintenance therapy improves progression-free survival.
Brain Tumors Feed Off Healthy Neurons
Short-circuiting neuronal lines of communication could help combat intractable brain tumors.
Early Pembrolizumab Ups TNBC Responses
PD-1 inhibitor plus chemotherapy elicits higher pCR rate, better event-free survival than chemotherapy alone.
FDA Offers Advice on Trial Design
Agency's guidance outlines when placebos and blinding should be used in oncology drug development.
Database Drives Biomarker Research
Researchers compiling data on cancer drug screens to identify genomic features that predict drug response.
First RET Inhibitor on Path to FDA Approval
New data from LIBRETTO-001 show high overall response rates in patients with advanced RET-altered lung cancer.
Collaborative Review Leads to Concurrent Approval
Under Project Orbis, Australian, Canadian, and U.S. regulators simultaneously OK drug combo for endometrial cancer.